Related Experiment Videos
[Study of primary hemostasis in vitro with the Platelet Function Analyzer (PFA-100)]
Guido Reber1, Françoise Boehlen, Pierre Fontana
1Division d'Angiologie et Hémostase, Hôpitaux Universitaires de Genève. guido.reber@hcuge.ch
Revue Medicale De La Suisse Romande
|April 21, 2004
Summary
The PFA-100 device assesses primary hemostasis using whole blood under high shear stress. It shows excellent sensitivity for von Willebrand deficiency but requires further clinical trials for antiplatelet monitoring and bleeding prediction.
Area of Science:
- Hematology
- Clinical diagnostics
- Hemostasis analysis
Context:
- The PFA-100 is a newer device for in vitro primary hemostasis assessment.
- It utilizes citrated whole blood under high shear stress conditions.
- Key pre-analytical variables include platelet count, hematocrit, and citrate concentration.
Purpose:
- To evaluate the diagnostic capabilities of the PFA-100 device.
- To determine its sensitivity for factor von Willebrand deficiency and platelet dysfunctions.
- To assess its potential for monitoring antiplatelet treatments and predicting surgical bleeding.
Summary:
- The PFA-100 demonstrates excellent sensitivity for detecting factor von Willebrand deficiency.
- Its sensitivity is lower for platelet function disorders.
- The device is highly sensitive to fibrinogen receptor inhibitors, with variable response to aspirin.
- Clinical trial data is lacking for its use in monitoring antiplatelet therapies and predicting surgical bleeding risk.
Impact:
- The PFA-100 serves as a valuable complement to traditional aggregometry.
- Further research is needed to establish its clinical utility in specific patient populations and treatment monitoring.
- Understanding its performance characteristics is crucial for accurate hemostasis assessment.